Q-omics provides the consensus-scored POMC profile across patient tissues and cancer cell-line models. POMC expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, POMC is differentially expressed in 11, with the highest sampling consensus in KICH. Additionally, POMC RNA expression shows 13,343 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight UVM, KICH, and LSCC as cancer lineages where POMC shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for POMC — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes POMC survival associations across molecular data types. POMC RNA expression shows survival associations in the most cancer types (22), followed by mutation status (4) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible POMC RNA expression–survival associations across cancer types. High POMC expression shows unfavorable associations in UVM and UCS, but favorable associations in UCEC, ACC, CHOL and THCA. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for POMC RNA expression.
This table summarizes POMC tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 2. The strongest signals are observed in KICH for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for POMC. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. POMC shows lower tumor expression in KICH, THCA, KIRP, LUAD and KIRC and higher tumor expression in LUSC. The KICH box plot shows higher POMC RNA expression in normal versus tumor tissue (log2 FC = −2.016, t-test p < 0.001).
This table shows molecular features associated with POMC in patient tissues and cancer cell lines. In patient samples, POMC shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, POMC RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and LUNG_SCLC.
